TransMedics Group, Inc. $TMDX Position Increased by FirstWave Capital Management LLC

FirstWave Capital Management LLC boosted its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 53.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 191,240 shares of the company’s stock after acquiring an additional 66,972 shares during the quarter. TransMedics Group accounts for about 5.6% of FirstWave Capital Management LLC’s holdings, making the stock its 3rd biggest holding. FirstWave Capital Management LLC owned 0.55% of TransMedics Group worth $12,702,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd purchased a new stake in shares of TransMedics Group in the 3rd quarter valued at approximately $29,000. Allworth Financial LP lifted its position in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares in the last quarter. Ascentis Independent Advisors acquired a new position in shares of TransMedics Group during the first quarter worth $30,000. Finally, North Star Investment Management Corp. purchased a new position in TransMedics Group in the first quarter valued at $30,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on TMDX shares. Needham & Company LLC cut their price target on TransMedics Group from $142.00 to $106.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Piper Sandler reiterated an “overweight” rating and issued a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Stifel Nicolaus raised their target price on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. UBS Group decreased their target price on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research note on Wednesday, August 5th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a report on Wednesday, July 1st. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, TransMedics Group presently has an average rating of “Hold” and an average price target of $124.18.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $89.98 on Friday. The firm’s fifty day simple moving average is $80.14 and its 200-day simple moving average is $92.21. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00. The stock has a market capitalization of $3.11 billion, a price-to-earnings ratio of 23.13 and a beta of 1.90. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The business had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm’s revenue for the quarter was up 20.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.92 EPS. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.